Andrew Huberman interviews mycologist Paul Stamets on fungi, immunity, psilocybin, and brain health
Andrew Huberman speaks with Paul Stamets, mycologist and founder of Host Defense, about the science of medicinal mushrooms.
Summary
Paul Stamets, widely regarded as the father of modern applied mycology, joins Andrew Huberman to cover fungi's role in immune function, the science of medicinal mushrooms, and the emerging field of mycelial intelligence.
Stamets presents clinical trial data — published in BMC Immunology — showing that a combination of agarikon and turkey tail mushroom mycelium significantly reduced adverse reactions to COVID mRNA vaccines while tripling antibody levels six months post-vaccination, in a double-blind placebo-controlled study of 90 participants. A second study of 50 participants showed statistically significant reductions in COVID symptom duration — approximately 5.1 days sooner for unvaccinated individuals who took the mushroom combination — along with reductions in coughing and sneezing, which are vectors of transmission.
Stamets argues that H5N1 bird flu — already present in 90 mammal species — represents a far more dangerous pandemic threat than COVID, with a potential human fatality rate of 40–50%, and that upregulating natural immunity through fungal compounds is a critical preparedness strategy. He describes a $2.6 million grant to screen 130 strains of agarikon for hyper-producing candidates active against H5N1.
The conversation covers the entourage effect of whole mushroom mycelium products versus isolated molecules, the biotransformation that occurs when mycelium is grown on rice (creating an immunologically distinct fermented product), and Stamets' distinction between mushroom fruit bodies and mycelium. He also shares the personal origin story of his obsession with fungi, tracing it to the influence of his late brother John, and discusses his daily regimen of agarikon and turkey tail capsules from his Host Defense product line.
The host briefly references his guest's enthusiasm for a 'tryptamines in the universe' concept in his closing remarks, and Stamets closes with a call for creativity, collaboration, and responsibility to future generations.
Key Takeaways
FULL TRANSCRIPT
The evolutionary relationship between fungi and animals
Paul Stamets: I'd like to kind of go back. We shared a common super kingdom called opisthokont. The opisthokonts were protists — single-celled eukaryotes — and as they differentiated, there was the holozoa and the holomycota. That's actually the branch that led to mycota, meaning fungi, and holozoa meaning animals. When the fungi became multicellular, it's called multicellularity, and that multicellularity allowed the fungi to absorb and digest their nutrients externally. The path that led to animals from the protists — when they became multicellular — is that we started encapsulating our nutrients, basically like a stomach, and we started digesting our nutrients internally. This elaborated about a billion to a billion and a half years ago. In the context of the cosmos, that's like yesterday — a lot of yesterdays.
What's really exciting to me, and so important for people to understand, is the complexity of these fungal networks. In a single cubic inch of soil, there can be one to eight miles of mycelial networks in enriched soil. There can be more than a million species of bacteria and more than a billion organisms co-inhabiting in this latticework of mycelium, which is a membrane. It sets up a microbiome. We know fungi produce antibiotics — penicillin, etc. This staves off pathogenic bacteria. We share in common many of the pathogens that afflict fungi — E. coli, staph, Clostridium, etc. So what the mycelium was able to do is create the basis of what we enjoy now as our food chain. It's the biodiversity of these fungal networks setting up microcosms of enormous complexity.
I just had an interesting conversation with an AI expert. When you think about the cross-talking between the receptors — when you have more than a mile of mycelium with more than a million species of bacteria, prebiotics setting up alliances with favorable bacteria, who then create a quorum to push back against pathogenic bacteria — it sets up an ecosystem of sustainability and cooperation. That sort of bilateral communication between all these organisms comes into agreement and alliance: we're going to create an ecosystem that gives rise to plants and animals, that gives rise to forests and food chains, that creates the detritus that then feeds all these organisms. They have a self-interest in their mutual survival.
The AI expert I had a conversation with just yesterday — this guy's an absolute genius — told me something I didn't know. I was advocating natural intelligence, not artificial intelligence, because of the complexity of the ecosystems that we're just beginning to understand. He told me something I did not know: we have come up to a data wall where 99% of discoverable data in the human experience has already been discovered by AI, and now there's a data deficit. Where do they go next? He told me that some of the biggest minds in AI have identified exactly what I'm talking about — natural intelligence. We need to tap into the intelligence of nature because of the complexity of this cross-talking of all these organisms and the biodiversity microscopically that leads to us as macroorganisms. We're 90% bacteria. This is a community of cooperating individuals, and there's cross-immunity and protection, and they have in common the healthy ecosystems that protect their own progeny and us.
So now we have to be really responsible citizens taking care of the ecosystem. This is very exciting. This is opening up doors to discovery that are heretofore unimaginable. Just because we don't know the mechanisms of action doesn't mean that it's not true. We can demonstrate healthy ecosystems. Do we know how they operate? No. We have a sense. But we know we make the investment in healthy ecosystems, and our bodies are ecosystems. We are a semi-permeable membrane. There's a constant cross-molecular communication from the ecosystems in which we live to our internal ecosystems. This multifaceted communication pathway is something where I think AI can help us. Natural intelligence will always exceed artificial intelligence.
Andrew Huberman: I love it. We're veering towards immunity. I just want to make sure I understand something you said earlier in the context of immunity — that these fungi, which are vast, have to combat bacteria. So they have mechanisms within them that allow them to do that. And I believe that's what's going to take us toward the idea that we can leverage those mechanisms to combat bacteria in us, and viruses, and other things. Before we continue down the path toward immunity, I have a question about the physical architecture of these fungi. I have two pictures in my mind. One picture is of flat fungi that grow out on things and maybe dive in between rocks and maybe grab onto the skin of animals and humans and live there under nails, between toes. And then I also imagine mushrooms growing out of the ground with a little stalk. I'm guessing there's probably a third category of airborne fungi. What other categories are there? And if you would — I'm also curious, if we were to look a mile above Earth down to the surface and then deep into the Earth and into the oceans, where would we find fungi? Like, where there's concrete outside, are they running underneath the sidewalk?
Stamets: Fungi munch rocks. They munch concrete. In fact, it's well known by road builders to get down to mineral earth because if there's any organic debris, shaggy mane mushrooms are known to break through asphalt. You can crush a shaggy mane mushroom with your hand, and yet it's got this herculean force to be able to break asphalt and concrete. Your question is very apropos, and a big surprise to even most of us mycologists — there's marine mycology. The oceanic depth of mycelium is just astonishing. More than a mile and a half down, they've done core bores and found all these fungi. The biggest reservoirs of fungi now, we think, are in the oceans, and that's just being discovered.
Realize that mushrooms are like the tip of the proverbial iceberg. There's mycelium everywhere, but mushrooms are made of mycelium — they are aggregates of mycelium. But mushrooms don't have a good immune system. They rot very quickly. Everyone knows you've got to eat mushrooms right away. But the mycelium is the immune system of the mushroom life cycle. It's the mycelium that we are really diving into that I think will have a paradigm shift in helping immunity of us macroorganisms interfacing with the immunological wisdom of these mycelial networks. That's what I'm super excited about, because our ancestors over literally millions of years have gone into this encyclopedic library of fungal candidates, and through trial and error — often times errors would end up killing you — we were able to select about 200 species out of what we think are two to four million species out there.
Think about mushroom species being miniature pharmaceutical factories. There are hundreds or thousands of novel molecules being expressed by fungi that are not occurring elsewhere in other life forms. Our ancestors selected out these different species, and we've now narrowed it down to about 200 species that we have great confidence are compatible with our microbiome. But more importantly, the mycelial networks are exponentially more powerful — ten to a hundred times more genes are being expressed by mycelium. That makes sense because mushrooms are designed to be eaten. They attract insects and microvorous animals to eat them. They want their spores to spread. But think about the immune networks that have to be in place in order for the mycelium to generate a mushroom. Mushrooms are the portal into this vast internet-like design system of the mycelium. It's the immunological wisdom of nature. This is why I'm an applied mycologist. I've focused ever since I was 14 years of age on what can I do with fungi.
Paul Stamets' origin story — a brother's influence and a lifelong obsession
Huberman: You were 14 when something sparked an obsession in fungi in you. Do you mind sharing what that was?
Stamets: My dear brother John, who unfortunately passed. We grew up in a small town in Ohio. We came from an industrial family, but we had a fully equipped laboratory in the basement. My brother John was into chemistry, and my father served on the US aircraft carrier the Intrepid, and we got the Intrepid's main radio for the whole aircraft carrier. John was six years older than me. He was going off to Yale University, and he would never let me do any experiments. He was a serious scientist. I wanted to blow up things. But he would park me in the corner and I could listen to coded messages behind the Iron Curtain. I strung a 200-foot wire with glass insulators for longwave radio transmissions and I was just in love with him — he was my mentor by far. He became my tripping buddy later on.
John went down to Mexico and Colombia and came back with these extraordinary stories of taking psilocybin mushrooms. He basically told me one time, "Paul, I don't have time to get into this, but this is a really interesting area." And so he stimulated my interest in fungi in general. I looked for psilocybin mushrooms for years and years and couldn't find them. I stumbled into chanterelles and porcinis and shaggy manes and bluets, and I went, "Well, I'm looking for psilocybin — I must have found all these edibles. What are they?" Anyone who has not experienced the joy of the eureka of discovering a multicolored beautiful mushroom by just luck or happenstance — it's this amazing experience that brings you out into the woods with your family and children. It's multigenerational. Families have secret mushroom patches they pass down through the generations. It builds a bridge multigenerationally.
John was also into edible mushrooms, but I knew a lot more about mushrooms than he did. So my mentor became my student, and there was great joy in my life just to be able to share this wisdom I was accumulating. My brother John — I'm so sad that he's gone. He'll be the best podcast interviewer ever because he was so smart. He unfortunately died from cardiac arrest. So that's why I do push-ups every day.
Huberman: We'll talk about your push-up regimen. I'm sorry for his passing. Your love for him and appreciation for him comes through in real form. As a younger sibling, I know the deep joy in being both the student and the teacher in the sibling order.
Primates, mushrooms, and the deep evolutionary history of fungi as food
Huberman: How long ago is it documented that humans first started eating mushrooms of any kind? Do we have any sense of when they started dabbling? Because it can be a risky endeavor.
Stamets: It's going to be a risky endeavor, but realize that most primates eat grubs, fly larvae, maggots. Flies are attracted to mushrooms, they lay eggs, maggots grow. There are about 21 or 22 primates, including humans, that eat mushrooms. There's a monkey in Bolivia that consumes more than 10 to 15% of its body weight per year eating mushrooms. So the primate-to-mushroom connection through grubs is very strong.
Starvation is a great motivator for finding food. You see these big bodacious soft mushrooms that have grubs in them. You would eat the grub and the mushrooms and come to learn that some of these mushrooms are actually quite delicious and nutritious. How far does it go back? I think it goes back in memoriam. It goes back to our very primate beginnings. The fact that we have more than 20 primates today that are known to eat mushrooms and know the difference between poisonous and edible mushrooms — think about that. They may not have language skills and they don't have field guides, but they have generational knowledge of how to select out of the forest the edible ones and avoid the poisonous ones. I don't think you can untangle the evolution of primates from their use of mushrooms in general. And of course it's a Russian roulette — if you're not careful, you choose the wrong species and you die. But isn't that true of how we found out what frogs are edible and what plants are edible? Humans love to experiment, and hunger is a great motivator for exploration of new foods.
Huberman: I know we're going to get to immunity soon, but I have to ask — in thinking about primate evolution, is there a world where our primate ancestors consuming mushrooms thereby consumed molecules that impacted the genome of developing fetal primates? In other words, is some aspect of brain expansion and evolution across primates linked back to molecules found in mushrooms? We know that protein consumption and fat consumption during pregnancy greatly enhances brain size and weight in offspring. More omega-3s, more protein seems to lead to healthier, larger brains. Could mushrooms have played a role?
Stamets: It's a very plausible and well-thought question, and my answer is I don't know. Obviously nutrition is helpful for human health, and the healthier a mother is, the better she can carry a child to birth. That's obviously logical. But you're asking questions that I don't have direct knowledge or an answer for, and I want to be careful what I say.
Huberman: I appreciate it. I have this fascination with the idea that because of the enhanced sense of smell that females experience during pregnancy, they may have been able to detect both poisons to avoid but also things that could potentially impact the short and long-term development of the brain.
Stamets: The danger here is that some of the most deadly poisonous mushrooms in the world are delicious — but it's your last meal.
Huberman: That's the best warning for why not to go out and pick a mushroom and eat it without getting educated first that I've ever heard.
How fungi bolster the human immune system — mechanisms and entourage effects
Huberman: Okay, so immune system. Most everybody nowadays understands that we have this thing called an immune system that's there to recognize self versus other and destroy stuff that is potentially going to harm us. How is it that fungi help that system thrive? And I'm interested in how fungi might do that indirectly by supporting the cells and the robustness of the immune system, as well as ways in which fungi within us can just do their thing and combat bad stuff through their own immune system.
Stamets: A classic example of more than one thing can be true — but more than a dozen things can be true. This is the entourage synergism. I like to trace back to my story about how I got involved with viral research and pandemics because I think it's illustrative.
In June of 2001, I published an article in a journal called HerbalGram, the American Botanical Council. In the 1970s, Dr. Frank Panov from the University of Wisconsin Medical School met me at a conference and said, "Paul, I'm a virologist. I found some antiviral properties in mushrooms. Can you get me the gypsy mushroom?" It was called Rozites caperatus, Cortinarius caperatus. It's a mycorrhizal mushroom — it grows in the forest and most mycorrhizal mushrooms we can't grow. So it has to be collected. Back in the day when Federal Express first started, I shipped him about 20 pounds of gypsy mushrooms. He ended up isolating a novel glycoprotein called RC183, highly active against herpes viruses.
I thought to myself, great, Frank — you found the antiviral properties of the mushrooms. I'm going to survey the scientific literature. So I did a deep dive and published a one-page article with all the scientific research I could find on antiviral mushrooms in June 2001. 9/11 occurred. A physician involved in the bio-defense BioShield program saw my article, reached out to me, and said, "Listen, we're really concerned about weaponizable viruses — smallpox in particular, flu, etc. We're doing a wide net. We need to potentiate host defense against potential pathogens." I had a laboratory, a small business — Fungi Perfecti, with a Host Defense product line. I created the business to do research. So I had amassed hundreds of cultures and hundreds of species. They gave me carte blanche and I could just shotgun. I sent them material. They did, I think, 265 assays for free, and I shotgunned massive amounts of material — mushroom fruit body extracts, the mycelium that made those mushrooms, those extracts.
When I got the research results back, they were phenomenal — especially against orthopoxviruses and against flu viruses. I got a lot of attention. I got more resources. Virologists were going, "What is going on?" You could actually listen on National Public Radio to myself, the deputy director of the FDA, and the head of the BioShield program. We were in the top 10 of more than 2 million samples surveyed. We were the only natural product in the top 10 of super selectivity against weaponizable viruses.
That localized into this old-growth mushroom called agarikon. Most mushrooms rot in a few days — that's true with oyster and shiitake and maitake mushrooms. But agarikon is one of the longest-living mushrooms in the world. It grows for more than 100 years. It grows in old-growth forests. It's now on the red list of extinction in Europe — you can't pick it legally. We still have it in our old-growth forests in northern California, Washington, Oregon, British Columbia, and also Montana and a little bit of northern Arizona.
In the 1980s, I started focusing on agarikon because it was such a mesmerizing mushroom. It's the only species in its genus and the only genus in its family. Dioscorides first described it in the first materia medica in 65 AD as elixirium ad longum vitam — the elixir of long life. So you have this elixir of long life, a longevity mushroom, used for thousands of years, growing in old-growth forests. We just published in G3: Genes, Genomes and Genetics the full genome sequencing of agarikon — the first one in history.
The COVID clinical trials — vaccine enhancement and symptom reduction
Stamets: In 2020, I was approached by a group of people who had seen our published research. "What can you do with COVID?" So we proposed bundling agarikon and turkey tail. We have a Host Defense product line — the very same material going into our nutraceutical product line. We bundled them together and published three papers on turkey tail.
The first thing the FDA said was, "We don't want to overstimulate the immune system." Most people die from the cytokine storm from COVID, Ebola, flu viruses — people die from overexpression of the immune system. Fortunately, we had a breast cancer clinical study from around 2012 to 2019. We found that when you grow the mycelium on rice, separate from the fruit body, it ferments the rice into a microfermented unique product. We published in the Journal of Inflammation Research that it stimulates interleukin-10 and interleukin-1 receptor antagonist — anti-inflammatory cytokines. So we could upregulate immunity but suppress the overexpression of the immune system by having these anti-inflammatory cytokines. We passed the test with the FDA. We also had all the safety data from the BioShield program.
We bundled these two things together. It's been privately funded through the Chopra Institute of Integrative Medicine at the University of California, San Diego and UCLA Medical School. We have 140 patients in two studies, and we published in BMC Immunology the results for vaccine enhancement. We published that one first because we have a natural product trying to mitigate COVID — you can imagine the blowback we would get. Half the country would just want to take that, and the more traditionalist side would think we're trying to create a replacement for vaccines.
We kept the complexity of the natural product in place. Our double-blind placebo-controlled clinical studies showed enhancement of mRNA vaccines from Pfizer and Moderna. The big result was a statistically significant reduction of adverse reactions to the vaccines compared to the placebo, which was the rice. So it's the mycelium on rice — immunologically a unique product, very different from and better than mycelium alone, very different from and better than the mushroom fruit bodies.
The real surprise came from Gordon Saxe, Andrew Shubov, Christine Hector, and other individuals who are part of this team — there are about ten or twelve co-authors on these papers. They decided, since they had banked the blood of these 90 participants, to have the patients come back six months later and draw their blood. This was not my idea — this is the genius of our team. They withdrew the blood, and it turns out — statistically significant — those people who took agarikon and turkey tail and had the vaccine had triple the antibody reservoirs against COVID than those individuals who just got the vaccine. Not only did we reduce the adverse effects of vaccination, but we extended antibody immunity — and they only took it for four days. Think about the extension of innate immunity.
Our hypothesis is that it elevates immunity to a higher state of readiness so your endogenous immune system can customize antibodies specific to the pathogens it's trying to protect the host against. The advantage of vaccines — and their vulnerability — is their hyperselectivity. You get vaccine evasion from the viruses because they're really good at targeting specific things, but then the viruses mutate and you have immunologically compromised people who are mutating all sorts of vaccine-resistant viral strains. This is why we have vaccines that are different every season — trying to navigate around the viruses building up tolerance.
We have a second study with 50 people who were recruited when they were sick. "Do you want to be involved in a COVID clinical trial using mushroom mycelium?" Just the mushroom, no vaccine. Some people actually did get the vaccine but still got sick. We had three ways of slicing this pie. We got two slices where we showed statistical significance. The third slice — we don't have enough people to understand exactly what happened. But what we found, which is very controversial but the data speaks for itself — a statistically significant reduction in headaches, muscle aches, sneezing, and coughing. Those last two are vectors of transmission. The fact that we were able to significantly reduce coughing and sneezing significantly reduces the vector of droplet dispersal.
When we look at the metric — how long until there was a 50% reduction in symptoms — people who were unvaccinated and took agarikon and turkey tail resolved 5.1 days sooner than placebo. Those who were vaccinated and got agarikon and turkey tail resolved 0.9 days sooner. Tamiflu only reduces your disease symptom period by about one day. We were able to show statistically significant reduction five days earlier comparatively.
We think we upregulate immunity and we've been able to decouple reactogenicity to the vaccines from immunogenicity — upregulated immunity. As you know, inflammation and immune stimulation go hand in hand. You get cut, you get inflammation. The fact that we're able to decouple these things is almost like an oxymoron in medicine. What is going on here? The proof of the fact is that patients reported and showed this. It's like aspirin — we didn't know how aspirin worked until the 1970s, but it was being used well before that. So this is where we come into this new area of enhancing conventional medicines. I believe in conventional medicines, but I think we need to elevate our immune system's ability to make conventional medicines work better. If we can elevate immunity to a higher state of readiness, that helps not only the individual but our communities.
Huberman: I'm going to attempt a brief summary to make sure I'm on board. By increasing the activity of the immune system but simultaneously decreasing certain activities of our immune system, you were able to carve this narrow path whereby people had fewer symptoms and yet were able to combat the infection more effectively. You also mentioned that because there was some enhancement of immune function, it raises the question — is that because of some sort of hormetic effect? Like when we take something that is a stressor, our immune system responds and that can actually be beneficial — like exercise, for instance, which has many benefits, among them our ability to combat infection, as long as we don't over-exercise and we sleep enough. So a skeptic — not saying this is me, but I'll play the skeptic for a moment — will say, "Okay, well, you're ingesting a little bit of something that's creating an immune response that allows you to deal with other foreign invaders." Is there any idea for or against that based on these particular species of fungi or the known mechanisms?
Stamets: That brings us into the discussion of the implications of in vitro tests — basically human cells in petri dishes — versus real-world individuals consuming this and what are the outcomes. It speaks to mechanisms of action. What we also published with lion's mane mushrooms and mushroom mycelium, as well as with turkey tail and agarikon, is that when LPS — lipopolysaccharides, which are endotoxins from bacteria, used in thousands of papers to stimulate inflammation — was applied, the human cells digitally expressed genetic responses that showed that under stressful conditions, it dampened the inflammation that would otherwise be exacerbated compared to those that did not. So it tends to temper the overreaction of the immune system. These are called biological response modifiers, and this is one of the mechanisms of action.
We can work and talk all day long about molecular genetics and different genes being expressed — there are over 500 differentially expressed genes from agarikon with PBMCs, human blood cells in petri dishes, that upregulate and downregulate. More than 500 genes involved in the immune system. This again speaks to the entourage effect. Will we get better with this research? I think we will. I'm happy that we now have 130 strains of agarikon in culture. We have different phenotypes — think about the varieties of tomatoes in a garden.
The story of the discovery of penicillin goes to Mary Hunt's cantaloupe of Penicillium chrysogenum. She found a moldy cantaloupe in Peoria, Illinois, and brought it back to their research lab. Even though Alexander Fleming and his colleagues found penicillin, they couldn't industrialize it. Mary Hunt's cantaloupe produced 200 times more penicillin than anything else that had been seen, which allowed for the industrialization of penicillin. Similarly, we're looking for super strains of agarikon. We just received notification of a $2.6 million grant to go into our genomic library of agarikon to find super strains that are active against a variety of viruses.
We already got lucky. In one of the articles we just published, we had an agarikon extract from the BioShield program in 2004 sitting on a shelf in a glass gallon mason jar for 17 years, then put into refrigeration for four years. We pulled out that extract — it's in 35% ethanol, so there are no beta-glucans, it's a supernatant — and retested it. It's massively active against COVID. The cells that got plaque when exposed to the COVID virus — the plaque is dead surface tissue, the cells die, and virions get spewed out — the cells then healed within five days. Twenty-year-old extracts, shelf-stable, active against multiple viruses. This is mind-boggling.
Now we have in vivo the clinical studies with humans. Here's a case of translational medicine. Penicillin was discovered because it was inhibiting staph bacteria in a petri dish as an accidental contaminant. That's in vitro to in vivo translational medicine. Now we have the beginning of the bridge from in vitro to in vivo to human clinical trials. The potential — totally hypothetical — is: what if we could enhance most vaccines by increasing immune readiness? What if we could enhance most anti-cancer drugs by elevating the immune system to a higher state of immune readiness, so these drugs with their target specificity can work better without the deleterious inflammatory consequences of non-specificity?
Huberman: I guarantee that half the people listening are thinking, "Great, let's enhance the efficacy of these vaccines," and the other half are thinking, "How can we reduce the side effects of the vaccines?" And then there's probably a third category that is very anti-vaccine. In my role as a science educator, you encounter all three. It sounds like these tools would be very useful in each and every case.
Stamets: I absolutely agree with that. These camps are pretty rigid — people rarely cross lines. But it sounds like everyone could benefit. I want to really highlight something. Most pharmaceuticals were bioprospected from plants and other aspects of the natural world. I think that can't be said enough. Because most people, when they think about the pills they get from a prescription or over the counter, know it's been synthesized in a lab, but I don't think they understand that those molecules were discovered in the natural world.
I'm not in the vaccine-of-the-month club. 30% of Americans surveyed do not get the COVID vaccine for fear of the adverse reaction two days later — headaches, insomnia, they can't go to work, can't take care of the kids, don't want to miss school. They would take the risk of not getting the vaccine and avoiding the virus. Think about 30% non-compliance in taking a vaccine because of fear of adverse effects. This is why, with Moderna and Pfizer, this is a force amplifier. It actually amplifies the efficacy and gets more people to take vaccines.
But vaccines, because of their hyperselectivity and the ability of these viruses to avoid vaccine efficacy, really means we should think about this in a wholly new way. What I have come to realize is the immune system is so much more complicated than what conventional medicine thinks. When you do bioguided fractionation — we did it with agarikon — I can tell you the active molecules we found against smallpox: inotodiol, dehydrosulfuric acid, and ferulic acid. These are polyphenols, ethanol-soluble. When we tested those molecules individually, they didn't have the same effect. We found active constituents through bioguided fractionation. You take a natural product, you go from highly polar to non-polar — water being polar, hexane being non-polar — down to a decision tree, testing each fraction: is the potency against viruses increased or decreased? That's called bioguided fractionation. That's where the majority of our medicines have come from.
But you can bioguided fractionate into inactivity, because think about all the receptors that are cross-talking. This is what I really believe — our immune system is like a sophisticated computer of natural intelligence. When you ingest something that it recognizes as being helpful for the whole system, there's cross-talk between these receptors and the immunological landscape saying, "Okay, open up your receptors — this is going to be helpful." Natural products have an entourage effect. Through the theater and science of nature, we have so many different candidates we haven't explored. We've only tested less than 0.1% of the fungal species that are out there. We will have some very powerful natural products still in our library of potential medicines that we haven't even explored yet.
Molecular medicine is fantastic — I'm not throwing it under the bus. I just think there is a bridge between these two that we can increase homeostasis. From my point of view, health and disease is a multifactorial equation. We have coefficient multipliers on one side, the end of which is disease. What can we do to have a force amplifier? I think mushroom mycelium is a force amplifier on the left side of the equation to make the end result on the other side of the equation better for the individual.
What to take and when — agarikon, turkey tail, and practical immune protocols
Huberman: Earlier you were describing this work on the immune system. I really feel like you're operating at the interface between natural products and traditional medicine in a way that I don't know many people are. The entourage effect seems intuitive to me, and I think it's starting to become intuitive to the public, especially in the wake of the pandemic. No government, no pharmacy can give you the one molecule that's going to solve all your problems in any domain. Cocktails of things that work and synergize are increasingly being looked at as beneficial. Could you share with us — for those interested, meaning me, I'm raising my hand — let's say I feel like I'm coming down with something. I'm getting that innate immune response, a tickle in the throat. Or I'm battling a cold or flu or COVID. What is this cocktail? Don't be bashful. I want to try it next time I get sick. When should I take it, for how long? Or is there something I should be taking continuously?
Stamets: I walk my talk, and I created my business Host Defense in order to do research. The research now is proving that our Host Defense products support immunity in healthy individuals. We have multiple peer-reviewed articles out. This narrative is picking up speed. I've been on the lecture circuit, around thousands of people. What I do is I take Host Defense agarikon and turkey tail. These are the very same materials we supplied in the COVID clinical trials. We cultivate them in our laboratories — FDA-inspected laboratories. We've had what's called no 483s, which is a pharmaceutical-grade level of inspection for our extracts.
In the wild, these two would grow in the same forest. But we take tissue cultures from them and bring them into the laboratory and grow them in pure form. Mushrooms that grow for 100 years — you can imagine agarikon is subjected to air pollution, algae, bacteria. Turkey tail mushrooms — anyone who's collected them knows they're a bracket mushroom, called turkey tail because they look like the feathers of a turkey. They're multicolored. It's called Trametes versicolor — versicolor means variable in color. Turkey tail has algae and also sequesters nitrogen through agrobacteria. So it's a polyculture. When you get a young turkey tail mushroom versus an old one, this is a problem with mushroom fruit bodies in general — they are parasitized by bacteria, they rot quickly, they're contaminated from air pollution.
One of my biggest concerns is mushrooms coming from China. I had someone tell me there's no pollution in China and they looked at me with a straight face. They are wedded to this concept that mushrooms from China are clean and pure. It's just contrary to my factual understanding and testing.
The in vitro grown propagated mycelium grown especially on grains — because epigenetically we're seeing the mycelium fermenting the rice creates a unique product — is like milk being added to Lactobacillus acidophilus. It creates yogurt. It's a fermented product. It's biotransformed. In our clinical trials, we used rice as the control. Rice is not a filler — it changes the rice into this unique immunologically powerful product that does not overstimulate immunity.
What I do is I take agarikon and turkey tail. It's what I took this morning — four capsules each of Host Defense agarikon and turkey tail.
Huberman: What dosages? I mean, I take four caps — and forgive me for interrupting, but I just know that as people hear this information, some people will be very curious. They want to know what to do. I, for one, hate being sick. I don't get sick very often, but I would love to be sick less often and move through whatever respiratory stuff more quickly.
Stamets: I cannot make medical recommendations. I can tell you what I am doing and I'd advocate people follow the science. I populate a website with my team — I have six full-time researchers, four PhDs. We've published about 65 articles amongst us in peer-reviewed literature. We curate a website called mushroomreferences.com. There are over a thousand references now, covering as many peer-reviewed articles on mushroom mycelium and mushroom fruit bodies as we can find, including adverse reactions — things that have been reported to be concerning about mushrooms, of which there are several. Shiitake dermatitis, for instance — some people get an allergic reaction to shiitake from even touching the mushrooms, and they can have a dermatological adverse event.
Yes, I sell a nutritional supplement product line. Why do I sell it? Because I wanted to do research. I couldn't get money for research. I applied to 10 NIH grants. We got two of them approved. The timelines are so long. But I can be an adventurous investigative researcher and dare to fail without suffering lack of tenure. I own my own company. I've used my company and my motivation was to do research. In order to do research I needed money. So I created a product line, and now we have the science that supports my intuition. I really want to save lives. What is your legacy? I want my legacy to be: wow, he was on the edge, he was an edge runner, he was way out there, but damn it, he was right on some of these things, and millions of lives have been saved as a result. That's the legacy I want to live.
Galileo had the same experience — he was opposed by the church. I just heard from someone at the Vatican. The Vatican admitted, "We were wrong about Galileo." And now they're interested in life on other planets. This is what happens when you push the envelope. But we need to have credible facts to support the arguments, because hypotheses become theories become actionable solutions. That's why I'm in applied mycology. I want actionable solutions. So you ask me what I take personally — I take agarikon and turkey tail from Host Defense.
Huberman: Do you take it going into an infection and through it, or is it a daily regimen?
Stamets: Great question. Prophylactically, I up my regimen prior to public contact. My partner and I live on a remote island in British Columbia. We live a surprisingly extremely quiet life, and then we're thrown into the vortex of the public. Before we go, we start upregulating our immune system by taking agarikon and turkey tail. Also, I'm getting older, so my immune deficit is increasing, and I want to upregulate my innate immunity. So I take it several days prior, during the duration, and then I back down to more of a maintenance dose. A therapeutic dose versus a regimen of maintenance are two different things — often times a four-times difference.
Huberman: Thank you for sharing your deeper and larger motivations. Your sincerity comes through. Your commitment to these organisms and how they can be useful to humans and to the ecosystem comes through with sincerity.
Stamets: It's not just me. There's a bunch of other mycologists.
Huberman: There's your humility again. I realize you're embedded in a context and an ecosystem of other scientists. I didn't mean to imply you've done this all alone. I asked about the actionables because some people will want to do this and some people won't, and that's fine. I will say, as a brief editorial on the scientific process — having had NIH grants and sat on NIH review boards for more than a decade and saw what that process is like, how it can serve and how it also has flaws — I think any scientist, NIH-funded or not, will say there are flaws in the system. Having a variety of ways to explore really good questions, which always requires funding, is critical to evolving the scientific and therapeutic landscape. You and your colleagues were early to this approach, and I just want to second that approach as somebody who also respects the traditional approach. Great science can be done many different ways and through many different channels.
Stamets: Yeah. And we should be collaborative. My best supporters have been my skeptics. They've taken me to the mat and I go, "Okay, where's the peer-reviewed articles? Here they are. Where's the double-blind placebo clinical trials? Here they are. Next question." And they have to face whether they actually have a prejudice. They were demanding this before, and now we've delivered it. Why are you in denial that natural products can be helpful for the immune system? It becomes a point where there is a scientific bias. Most good scientists — and this is why my best supporters have been my skeptics — many of my supporters in the BioShield bio-defense program feel vindicated for supporting me now because they've seen the clinical studies.
H5N1, pandemic preparedness, and the case for natural immunity
Stamets: I don't want to be an alarmist, but let me mention something that's really important for your listeners to understand. COVID is not the last pandemic. In Washington state right now, two dairy farms are in quarantine because of H5N1 bird flu. Bird flu has jumped to 90 mammal species — 90. Killing seals, sea lions, all these birds you know about, but also killing marmots and all sorts of other mammals. And the fatality rate of H5N1 if it hits humans is about 40 to 50%. That's going to make COVID look like a minor viral pandemic. The fact that it's jumped from birds to now 90 mammals is a warning bell.
The virologists I know who are involved in bioweapons defense — and just three weeks ago the heads of AI platforms said the biggest threat to humanity's extinction is bioweapons being engineered by artificial intelligence. This is the inexpensive bioterrorist weapon: to create a viral pandemic with specificity. This is something we should all be concerned about. So this is why I believe in natural intelligence upregulating natural immunity, because your sophisticated immune system has the wisdom to be able to create the antibodies to protect the host — the system, you — because of this microbiome that we've come from, with the mycelium and this plurality of individuals who are unified to protect the system. You are a natural product, are you not? And natural products being used with each other is the lesson of evolution. So it should be all hands on deck.
I am so honored that a medical foundation with virologists and scientists looked at all of our data and, in collaboration with a well-known university here in California, has awarded us $2.6 million to look at every strain of agarikon we have — 130 strains — for hyper producers. We want to find a Mary Hunt strain against H5N1, like she found with Penicillium chrysogenum. If there's anything I can communicate irrespective of me, irrespective of any ego or money, the investment in biodiversity is an investment in our biosecurity. These are rivets of an airplane. How many rivets will we lose before the system dismantles?
We have factory farms, unprecedented transportation of individuals. One person on an airplane — like with Ebola, they had to test 200 people who were on an airplane with someone who was really sick. He went to Kenya and now they're tracing and tracking Ebola because of the infrastructure. We have so many potential viral pandemics. And the other thing people may not understand is you can co-incubate multiple viruses and get horizontal gene transfer. The bacteria that are also growing can become a platform for horizontal gene transfer. We are in unprecedented times of population density, transportation, factory farming, and now AI and people who want to create Armageddon.
What I'm offering is a platform, a foundation to elevate conventional medicines to a higher state of efficacy. We have to prove it. But for instance, I published in Nature with my colleagues on reducing viruses in honeybees — up to 14,000 times less viruses in honeybees in 10 days. The deformed wing virus is a pandemic against beehives. Apis mellifera, the honeybee. My colleagues at Washington State University, some of my employees, and scientists from the USDA — Jay Evans, a renowned virologist — are all co-authors. He's never seen anything work so well. We were able to do extracts of these polypore mushrooms in sugar water and give it to the bees, and in 10 days there was a 14,000-times reduction in viral titers of the deformed wing virus. The wings become weakened and deformed, and bees used to fly for 7 to 10 days and now they're flying for four. One bee pollinates a thousand flowers a day. Think about 4,000 to 5,000 fewer almonds and cherries and apples. It's a threat to biosecurity. We are in a bee apocalypse right now — the worst die-off of honeybees in the history of this area.
We met with the FDA and we've been trying to get this approved. Number one, they don't want to hear about viruses. I actually had an FDA regulator on Zoom look me in the eye and say, "Okay, we want you to characterize all the constituents inside this natural product." And I said, "May I say something?" She said, "Yes." I said, "There are more than 200,000 constituents in this product. You want us to characterize every single one of them?" And she literally couldn't say anything for about 45 seconds. You take a pharmaceutical that's 99% pure — the impurities are less than 1%. That modality of thinking, that you want to test all impurities and identify the active constituent — this is where natural products face this huge barrier of regulators. You cannot get these products to market because a bureaucrat in Europe has outlawed the selling of mycelium because they say it's a novel food. But mushrooms are made of mycelium. So one regulator makes a decision that denies Europeans the ability to buy agarikon or turkey tail mycelium for pandemic defense.
The shift in public perception — from fringe to mainstream
Huberman: There are some parallels within the realms of physical health and mental health tools that are purely behavioral. I'm 51. You're about 20 years older than I am.
Stamets: I'm 71.
Huberman: All right. So you and I can remember a time where if somebody meditated or did what would now be called breathwork, or did yoga, or lifted weights for that matter, they were part of an extremely niche community that was either ridiculed, ignored, or just considered fringe. Now, having gone through the 80s, 90s, and early 2000s with tons of studies on the benefits of resistance training, meditation, breathwork, yoga — and now actually great work from Chufu Ma's lab at Harvard showing that acupuncture and its specific arrangements of needle and pressure points can liberate certain molecules — now everyone goes, "Oh yeah, meditation can help make you more calm, more focused." But not but ten years ago, that stuff was considered pretty wacky. The practices came first and the validation of those practices came later, many through NIH-funded studies. I think times are changing. The younger generation, 35 and younger, grew up in the context of people just doing this stuff. Things are shifting toward the better.
Stamets: Well, we're left coasters. We live on the West Coast. There's always resistance to change. I am a blend — I'm conservative in some ways and socially liberal, but I also come from a farming family of wheat growers. We have thousands of acres of wheat in my family. Talking to my relatives who are farmers, any potential change from the system is very dangerous. Their margins are so thin they can't risk change. Let the scientists do that, prove it, and then give us a new deliverable that we are confident in. It's natural for even a conservative scientist to resist change. They have to worry about reputation, tenure, and failure.
This kind of segues into my psilocybin experience. When I first went to academic conferences interested in psilocybin, two things happened. One, it was like I was a leper. There was a force field. I'd walk into a crowd and the force field would distance people from me. Here comes the hippie interested in psilocybin. It was extraordinary. I refuse to be an apologist for my interest in psilocybin. And now it's a revolution sweeping the planet. There's a revolution from the underground. 2.5% of Americans admitted they used psilocybin last year.
Huberman: Microdosing or macrodosing?
Stamets: Both. That's over 8 million Americans by my calculations. Do you think this is because of the studies on repeated use of psilocybin as beneficial for major depression?
Huberman: Yes. The clinical trials for people who are depressed, PTSD, all sorts of other conditions — and then increasingly there is evidence that psilocybin increases neuroplasticity and creates new neural networks. That's the area we've focused a lot of attention on. The observational studies — and this is easily discoverable — show a statistically significant association of induction of calm with a person who's done one dose of psilocybin, partner-to-partner violence reduction, and with two heroic doses of psilocybin, 90% of people addicted to tobacco compared to the nicotine patch were not smoking cigarettes one year later.
Defining heroic doses, therapeutic protocols, and categories of risk
Huberman: Can you define heroic dose?
Stamets: Let me define it several ways. For those who know Psilocybe cubensis — the golden tops, the most commonly cultivated psilocybin mushroom in the world — a heroic dose is typically over 2.5 grams. Really, the hero's journey is around four to five grams. This is where set and setting is so important. Therapy afterward is so important. Preparatory work is really important so you understand what you're going to experience. There's a great nonprofit in Canada called Roots to Thrive. Dr. Pamela Kryskow is one of the co-founders. They really have a lot of experience with end-of-life care, permitted by the Canadian government on a case-by-case basis.
Huberman: We should touch on legality and categories of humans for which there could be elevated risk. As far as I know, psilocybin has been decriminalized in the United States in a few places, but is still — and I have to pronounce this very clearly — illegal to possess or sell. That's my understanding.
Stamets: Absolutely. Very important. If you cross state lines, you're involved in interstate transportation of a Schedule I drug. Possession of it is federally illegal. Transportation across state lines is very federally illegal. Oregon and Colorado have decriminalized. I've spoken in front of two city councils in Washington state, and there was unanimity of the city councils to decriminalize the possession of psilocybin to the lowest priority of law enforcement. They made it less of a violation than a parking ticket. So they decriminalized it — didn't legalize it. Olympia, Seattle, Mount Vernon, Port Townsend.
Huberman: What about categories of risk?
Stamets: People who have a genetic or familial predisposition to psychosis or bipolar disorder need an abundance of caution. This is very, very serious. They need to be pre-screened. We need to have adults in the room on this. This is not a party drug. This is serious medicine.
70% of people typically have a positive experience. The COMPASS Pathways psilocybin studies are showing about 40 to 45% resolution of treatment-resistant depression or major depressive disorder. It's clearly a very powerful medicine — it doesn't work for everyone. Very interestingly, Johns Hopkins — Roland Griffiths, who unfortunately passed away — he really led the charge on this. They had a retrospective study 14 months after heroic doses of psilocybin. They interviewed the individuals, and about 70% described it as an extremely positive experience, among the top five positive experiences of their life. 30% of the people described it as a difficult experience. But the 70% of people, 14 months later, determined that the act of re-remembering the experience was psychologically beneficial — they relived the experience, reliving a neural pathway and a memory. The 30% who had a difficult experience had no adverse effects post the experience. 14 months later, they just said, "Not for me. I'm not going to do that again. That was too difficult."
People with schizophrenia, psychosis — absolutely, this is truly a mindbender. But so many people can benefit from this. People need to realize this is the anti-addictive drug. So many people when they take a high dose of psilocybin look at the mushrooms the next day and say, "No way. I'm not touching those." Many people use it one time in their life. Think of that. This is why for opioid use disorder, for tobacco, for alcoholism, for obsessive-compulsive disorder — which is what we're involved in right now — this seems to reprogram not only the neuroscape, but we know there are dendritic tips being formed from the tips of the axons. When these dendritic spines grow out and the adjacent axons touch each other, you have synaptogenesis and then neuroplasticity of a new neural pathway. You have another way of breaking your addictive behavior because you're not stuck in a rut. That's what's so exciting — the neuroplasticity benefits of psilocybin.
Everything we're doing right now, Andrew, is related to the health of our nervous system. Seeing or listening or me trying to formulate thoughts is all based on the health of our nervous system. I think psilocybin will go down as a paradigm-shifting drug rediscovered that could have the most dramatic impact for the health of individuals in society of any medicine discovered in history.
Huberman: That's a big statement. I spent some time with the clinical trials on psilocybin for major depression, a little bit on the data for OCD — and I should point out we're not talking about OCD of the "this person is really nitpicky" variety. We're talking about people whose compulsive behaviors actually strengthen the obsessions, and that's a vicious loop that's very detrimental to everyday living. So if these things can provide relief, and the clinical trials are very encouraging, I'm on board.
I do have a question. Mechanistically, we know that psilocybin can create new neuronal connections in the brain, maybe unmask existing connections as well. From what I understand, I've been intrigued by the paradox where plasticity is great, but directing the plasticity toward a particular endpoint — the resolution of the depression, of the obsessions, of the excessive ruminations — that's the goal. It's not plasticity, it's directed plasticity. And there I feel like qualified therapy plays a critical role. It's not clear that people can just freestyle this. The big question in the psychedelic therapies realm is: are the thoughts, the unusual experiences during those psychedelic sessions critical to the clinical outcome? Because ultimately there's also a lot of neurochemistry happening that facilitates plasticity. Maybe we don't need to separate those two. But I think if people are going to use these powerful compounds to try and be healthier, it's going to be really important to figure out what should they be asked during these sessions. I don't think any of that is standardized. We can say more about dosage and strain than we can about what a good psychedelic therapy should look like.
Stamets: Absolutely. It's so important. Let me bring it back from my perspective. My father — who was anti-drug, a pro-Nixon guy — in his 70s said to me, "Paul, how long do mushrooms stay with you?" I was blown away. He never asked about mushrooms before, but somehow they were different to him.
The father considered the father of American mycology, Alexander Smith, also in his 70s, published a monograph on the genus Psilocybe — it contains most of the psilocybin mushrooms — and he studied psilocybin mushrooms all of his life but had never eaten them. He asked me, "Paul, I trust you. I want to do psilocybin mushrooms with you." I had two father figures who asked to do psilocybin mushrooms with me, and I turned them both down. I turned them both down because I knew the therapeutic element was so important.
For listeners who haven't had this experience — you have what can only be best described as an oceanic experience where the ego dissolves and you feel connection with nature and the universe. You realize you're just a whirlpool of molecules that have formed into this body. Before you were born you didn't exist, and after you die you don't exist in the same form. But this unanimity of being connected to this big concept — we can argue about what name to put on this concept or what this force is, but this oceanic feeling is a high predictor of resolution of PTSD and depression. The individuals who don't have this oceanic feeling seem to correlate with not having as many benefits.
The reason I turned down my father and Alexander Smith is that the next day I was literally leaving. I asked both of their wives, "Will you also take psilocybin mushrooms with us?" Both of them said no. I didn't want to be the wedge in their relationship — someone who has the most spiritual experience of their life and the other person has no idea what they're talking about, and then I disappear. You have to have a therapeutic support team.
This is what Roots to Thrive does. Their program is up on the web. I highly recommend people look at Roots to Thrive and look at their model. They do group therapy, six to eight individuals. It started with end-of-life anxiety, typically stage four cancer. It's become much bigger than that now. You end up with a community of souls — people that you learn with prior to the experience. Then after the experience, they have new friends, new colleagues, a community of people they can talk to. So many physicians — you walk out of their office, you're the patient, goodbye. The patient goes, "Wait a second. I thought we were friends." No, you've always been a patient. The Roots to Thrive model creates talk-therapeutic benefits not only with a trained therapist but with individuals who have a shared common experience and feel new relief.
So many of the patients in Roots to Thrive have been told through my partner, who is one of the main movers of this, that they have become the therapists to their family. They're saying, "I'm dying — hey, don't be worried." And the family's going, "What's going on here?" Before they were anxious about dying, and now they're saying, "Family, chill out. It's okay. I know what's going on here." And surprisingly, many of them are not dying. No clinical trial has been done on this, but when you're happier, your immune system upregulates. When you're depressed, you have an inflammatory state and your immune system downregulates. So mind over body clearly has an effect here.
The therapeutic element you mention is absolutely critical. This is why I want to say we have to be adults in the room about this. These are powerful medicines. These are not party drugs. We need regulation. It's surprisingly coming from me, but we need regulation. The dangers of not having regulation, purity, and this therapeutic regimen — we don't want to fumble the ball on this. It's too much potential good for society.
The bipartisan movement toward psychedelic medicine and psilocybin's broader social potential
Huberman: I want to be clear — I'm revealing my personal bias, but with all the cautionary points that came up earlier in mind, amen to that. It's kind of ironic that the fastest movement we've observed for psychedelics — in particular ibogaine and psilocybin, and the non-psychedelic empathogen MDMA moving toward FDA approval, they're not there yet but it seems like they're headed there quickly — has been through this alliance between, let's just call it what it is, the left and the right. Rick Doblin of the MAPS Initiative and Rick Perry, former Republican governor of Texas, joined arms in this, and things are moving pretty quickly. Who would have thought that during a Republican administration, psychedelics would get accelerated toward the FDA finish line?
Stamets: And they have not crossed yet. So I say this with optimistic anticipation. It's really this bipartisan effort that has made it happen. I don't think the Republicans could have done it alone, and I don't think the left could have done it alone. It really feels like there needed to be, sadly, a mental health crisis and then the exploration of these medicines to get us here. I think in 2027 we're going to see at least one of the three medicines I mentioned move to Schedule II, III, or IV as soon as possible.
What you're speaking about is that most of us have families of diverse opinions politically and religiously. My mother was an arch conservative, a deeply devoted Christian. And I've learned that in Christianity and Judaism, there are psychedelic Christians now who do one dose of psilocybin and feel like it affirmed their religious beliefs — they don't have to do it again. I think psilocybin makes nicer people. It makes us more tolerant of each other. We have so much more in common. 95% of us have the same common beliefs. It's social media and bots and clickbait that exploit people getting pissed off or excited or falling for it. This is really monetized and brings out the worst in society.
What happens with psilocybin is a reboot of the system. Most of us have had family members or friends afflicted with the opioid pandemic, and the vets coming back with PTSD — having these heroic doses and then seeing these people change, it's good news. It's a pebble in the pond of positivity. You don't want to talk about your addictive relative or the negativity. That's something you want to keep quiet. When you see somebody heal and you can champion their cause, you become a cheerleader: "Oh my gosh, I was against this." Like Rick Perry — he sees the benefit and says, "What was I thinking?" This is where it crosses the political divide.
I can't help but say it's ironic that during this administration they had the courage to do something that previous administrations knew they should have done but were afraid of losing their base or losing a few votes. We're at a new day, and I hope this never goes backwards.
I'll talk about the new normals. When you look at these studies, there's therapeutic use of psilocybin for treating people with mental health or psychiatric disorders. But we're all kind of on the spectrum — we have good days and bad days. A family member dies, it's a tragedy. So we all sort of move back and forth in this emotional psychological spectrum. What about all of us normals? What about prevention of addiction, prevention of PTSD, prevention of depression?
I'm going to say something very controversial, but I absolutely believe it to be true. When you look at the cost-benefit ratio of preventing crime, preventing violence, preventing depression, addiction, PTSD — psilocybin mushrooms should be available for everybody for free, because the return on investment to society, in the many billions and billions of dollars — the recidivism reduction, the reduction of the number of people going to courts and prisons — this is a huge paradigm-shifting potential breakthrough for society. It just makes more congenial, nicer, and I believe more intelligent people. We have a crisis in creativity. We have a crisis in immunity. This is where this subject field is so exciting to me.
There are 306 clinical trials on psilocybin at clinicaltrials.gov as of this morning.
Huberman: 306. That's impressive. Every one of them had to go through an IRB board.
Stamets: Yes. An institutional review board to make sure that there are safety measures in place because these are human clinical trials. Lots of pre-clinical animal data as well as in vitro data.
When I say psilocybin mushrooms should be made free, at the same time my sister would never take a psilocybin mushroom, but if it were approved by the FDA as a pharmaceutical and she needed it, she would take it. So there's universality of use. There's plenty of people for both the pure pharmaceutical as well as the natural form. But I think we do need to have intelligent regulation by the government. We need to set up programs. In Europe, for instance, all pharmacies and pharmacists are trained to identify mushrooms. When you want your mushrooms identified in Germany, you go to a pharmacy and they're trained on identifying the best edible and the best poisonous mushrooms. That's kind of what we need — that sort of infrastructure where, if you want to do this, okay, we have a week-long therapeutic program, enter this, you'll be given it, and you'll have follow-up. And so many people, it's just a once-in-a-lifetime experience. If you could improve your life for the rest of your life and it takes four to five hours — the investment in making your life fundamentally better for four to five hours is just a massive return.
Microdosing, the Stamets Stack, and the psychomotor tapping study
Huberman: Can I ask about microdosing? You refer to the heroic dose as two to three grams in many of the clinical trials, done once or twice with therapy, and then there's the heroic doses of four to five grams. What is a microdose? What qualifies as a microdose? Is it less than a gram, and how often are people taking them? I'm aware that you were involved in a study of microdosing — a self-report of positive and negative effects. Maybe you could summarize that study and tell us what constitutes a microdose in terms of milligrams and frequency.
Stamets: Everyone's different and everyone has different sensitivities. A microdose by definition is subsensorium — below the level that you feel an effect. That's what a microdose is. In the Psilocybe cubensis scale, one gram at 1% concentration is 10 milligrams. 10 milligrams is clearly a liftoff dose. A microdose is usually one to three milligrams for most people, normalizing across the landscape.
Huberman: People can feel 10 milligrams?
Stamets: Oh yeah. Of the pure psilocybin. One gram of mushrooms is 10 milligrams. One-tenth of a gram is 1 milligram. The hero's journey starts at 2.5 grams, or 25 milligrams. What is a micro versus macro dose in terms of the actual mushroom? One-tenth of a gram versus five grams. One-tenth of a gram is 1 milligram. One gram is 10 milligrams. Five grams is 50 milligrams. The FDA has approved 25 milligrams, or 2.5 grams of mushrooms, as the standard dose. That's why most clinical trials are 25 milligrams — 2.5 grams of mushrooms at 1% concentration.
Huberman: So let's just highlight that — 2.5 grams of Psilocybe mushrooms at 1% concentration is 25 milligrams. So when people hear "25 milligrams" or "2.5 grams," that's an enormous difference. They're talking about the actual mushroom versus the chemical in the mushroom.
Stamets: Now realize that 99.9% of the uses of psilocybin are in psilocybin mushrooms. Maybe a few hundred to a few thousand people have taken psilocybin the molecule. So the real-world use of psilocybin is in psilocybin mushrooms, which has all these other tryptamines involved — so there's an entourage effect.
We published — Dr. Pam Kryskow and colleagues published a paper on four individuals who took both psilocybin the molecule and psilocybin mushrooms in their natural form or an extract thereof. They interviewed them, and all of them preferred the natural form. The pharmaceutical had a quick liftoff, it felt chemical, and then had a quick descent.
Huberman: Sounds like most pharmaceuticals.
Stamets: Yeah. The psilocybin mushrooms had a little bit delayed but also a quick takeoff, but it had a long tail. And that long tail the patients felt gave them time to reflect. Some of them reflected that they felt connected with the natural world. When you go back to psilocybin's lineage — the molecule goes back to Albert Hofmann in 1958 — when you're taking the mushrooms, you realize there could be several million people on the planet at the same time taking psilocybin mushrooms. You are taking a journey with a collective consciousness of millions of other people who are simultaneously entering into this space. Your lineage goes back centuries, thousands of years, and communities across cultures. The sense that you're part of this community that goes back in history and is tied to nature — compared to a pharmaceutical, which is great, but as one patient said: "If I only had the pharmaceutical, okay, it works, I would take it. But I prefer the mushrooms."
That's illustrative of where we need to go. Standardization is important because you need to understand what you're taking. But just your very diet affects your sensitivity to these substances.
Let me go back to microdosing. There's microdosing, medium dosing, and the high-dose therapeutic dose. The sweet spot that we're increasingly paying attention to is medium dosing.
Huberman: And in mushroom weight, what is that?
Stamets: On the order of half a gram, which would be like 5 milligrams of pure psilocybin. It's often called the museum dose. You know why it's called the museum dose? It has been a common practice for a group of friends to take a small amount of psilocybin mushrooms and then go to a museum. You may have encountered these people occasionally. They're unusually happy. They're visually stimulated by everything in the museum and the artwork, but they typically wear sunglasses because the pupils of their eyes are so dilated that if they took off their sunglasses, it would scare people — they have no whites in their eyes.
It's called the museum dose because it's a liftoff dose — it's sensorium. But it only is sensorium for a very short period of time. I don't like making the analogy to alcohol, but it'd be like drinking half a cup of wine real fast and feeling a little bit of a liftoff for a few minutes, half an hour, and then it goes down. But this is not the five-hour deep journey.
The sensorium dose we think is important because activating the 5-HT2A receptors, you're actually engaging — there are more 5-HT2A receptors in your gut, and the vagus nerve connection with the mitochondria cascade occurring from the vagus nerve hasn't even been explored. We're all talking about the prefrontal cortex and 5-HT2A. Psilocybin is a prodrug for psilocin. So 10 milligrams of pure psilocybin is 5 milligrams of psilocin.
Huberman: Just to clarify — the prodrug is causing the release and activity of this other molecule, which is then the bioactive molecule. And you mentioned the 5-HT2A receptor, a particular category of serotonin receptor, which seems to be the basis for a lot of the therapeutic effects of magic mushrooms.
Stamets: Yeah. But there's also TrkB engagement — the receptor for BDNF. There's more than one receptor group being engaged. The museum dose creates a liftoff experience that's sensorium but is not intoxicating. You feel it, and then it goes away. You wouldn't want to drive.
But there are so many reports of extraordinary athleticism. Yesterday I heard about a person who's a professional dart player. He told me about the museum dose and came up to me and said, "Yeah, I've been doing the museum dose. I'm a professional dart player." There are many examples of this — from martial artists to boxers to people involved in baseball. Of course, it's dangerous for most people. I'm not advocating it. Please don't do this.
Huberman: Don't experiment on game day.
Stamets: Well, the golden rule around all substances and performance is that best competitions tend to emerge under the similar conditions to which you practiced. But it maybe is allowing people to access a plane of mental and physical performance that they couldn't otherwise.
You've developed muscle memory in skills. Once you develop those skills, there are psychomotor benefits enhanced by psilocybin becoming psilocin and binding with these receptors. We know that visually you have a lot more information. Hearing seems to improve. The colors, everything lights up — because you're seeing more of the spectrum. You have more neural activity. And it's not artificial. Back in the 60s and 70s, psychedelics were thought to make you see a non-reality, something that doesn't exist. Now, most of us believe you're seeing reality in a better way and more clearly than you've ever seen it before.
Huberman: As a neuroscientist, I think we should highlight what exactly that means. Our sensory apparati — our eyes, our ears, our touch receptors — are extracting a pretty narrow wedge of physical information in the world and then creating these abstractions in our brain of what's out there. On psilocybin there may be a wider wedge in certain senses, and an integration of different senses. Certainly there's more perception at the level of overlap between the senses. Some people experience synesthesias on psychedelics — you touch something and the contour of that surface matches to particular frequencies of sound. That's not uncommon. May I ask about the benefits and any potential side effects observed in the study on microdosing?
Stamets: Yes. My colleagues at Quantified Citizen out of British Columbia — I think we got up to 25,000 participants. We published two papers in Nature Scientific Reports, observational studies. These are self-reporting. They enrolled, created a baseline, stated their motivation for taking psilocybin mushrooms, how much they were taking, what they were combining it with, etc.
The first paper we published in Nature — what the editors really liked about it was that the two groups were so well weighted. We had more non-microdosers than microdosers in the study — about 4,500 non-microdosers, a few hundred fewer microdosers. The results showed tremendous improvement against depression, PTSD, and anxiety. Those were the ones that were really significant in the measurements. The blowback is expectation — you're in a community of individuals sharing this experience. Every medicine has a coefficient factor of expectation. The placebo and nocebo effect are real.
What was really interesting is I intuited that we could enhance psilocybin's benefits if we bundled it with niacin, because psilocin is a vasoconstrictor. Niacin is a vasodilator — vitamin B3, the flushing form. Vasoconstriction neuropathies often present as deadening of the fingertips and toes because the neurons get starved of blood and they atrophy. So I thought the flushing form of niacin — when you take it you feel itchy, you get red, it's a vasodilator — if you're going to offset neuropathy, why not have a vasodilator with psilocin, which is a vasoconstrictor? You get more blood and more psilocin to the endpoints of the peripheral vascular nervous system.
So I came up with something called the Stamets Stack, and I named it after myself. Doctors can name diseases after themselves — I named it after myself. I was tired of getting ripped off. So many people would take my ideas and not give me credit. So I'm going to tag this thing. The Stamets Stack is psilocybin or psilocin, niacin, and lion's mane mushroom mycelium.
In this Nature Scientific Reports study on microdosing, there was significant measurement of increase in mood and decrease in depression and anxiety. But we were criticized that this is all the placebo effect of expectation. So I asked my colleague Dr. Pam Kryskow, "Don't we have something that's not related to expectancy?" And she said, "Yes — we have the psychomotor test, the tapping test. How quickly can you tap your two fingers in 10 seconds?" So we put the tapping test in the microdose app that people could measure. Compared to non-microdosers after 30 days — there was a learning period for a few days so you could practice — the people who took psilocybin at a microdose level, again a tenth to a third of a gram of Psilocybe cubensis, and those who did the Stamets Stack — in 30 days the tapping frequency for the stackers went from 43 to 63. That's a psychomotor benefit. You can't say that expectation increased your tapping frequency.
That really struck me. Think about walking. Think about typing. Think about playing guitar. Think about a teacher trying to play the piano when they're older. Think about not falling going to the bathroom as you get older. This could be a neurological tonic that can help improve your basic neuroscape.
Now, unbundling this — is it the niacin or is it the lion's mane? I'm increasingly thinking that niacin is a force multiplier. Ironically, at clinicaltrials.gov, of the 306 clinical trials, at least 20 use niacin as the active placebo — because the flushing occurs in 20 minutes, they wanted to make sure some people felt something. So people are teaching away from what I'm advocating. But I think niacin is an amplifier. I think lion's mane also adds another dimension for remyelination. The dendritic spines that are being formed, I think, are augmented with niacin. More blood flow just makes sense to me as an amplifier to help psilocin be more neurologically beneficial.
Cordyceps, lion's mane, and the science of cognitive enhancement
Huberman: That brings us to cordyceps and cognition and memory. Could we talk about cordyceps and lion's mane? I get asked about these quite often and have since the beginning of this podcast back in 2021. Some of the earliest questions were, "When are you going to talk about cordyceps? When are you going to talk about lion's mane? When are you going to talk about reishi?" What are some very top-contour statements that you feel comfortable making about the role of fungi in improving memory, cognition, and some basic known mechanisms? We're not talking psychedelic mushrooms now — we're talking cognitive enrichment of some sort.
Stamets: I would refer people to mushroomreferences.com — there are peer-reviewed articles there. Cordyceps is really a big bucket because there are multiple species. It turns out that when they did DNA amplification, they got five different species coming out of Cordyceps sinensis fruit body in the Himalayas. When scientists would take a piece of tissue inside the stroma and put it in a petri dish, they'd get a fungus to grow and say, "Oh, I got cordyceps." But it turns out that in this stroma there are multiple species of fungi coexisting. One of them was Cordyceps sinensis, then it became Ophiocordyceps sinensis. Another one is Hirsutella sinensis. Another one is Paecilomyces hepiali. So you had this war going on among mycologists saying, "I got the real cordyceps." Cordyceps militaris is also another cordyceps that is much easier to grow.
The problem with Cordyceps sinensis records is that we don't know which cordyceps we're actually studying. What we do know is that it increases adenosine and oxygen uptake. The study that's most believable, I think, involved about 73 patients with Cordyceps militaris — they primed themselves for two to three weeks and it increases the ability to perform. They're taking cordyceps at gram dosages.
Huberman: Is time of day relevant here?
Stamets: I can't speak to that. I don't think it happens that fast. I don't think that happens that fast with reishi mushrooms and sleep — I think that does happen. Reishi mushrooms can enhance your quality of sleep. Lion's mane mushrooms — cells take time to divide. This is why the heroic dose of psilocybin versus titrating it with medium doses — if it's going to be neurostimulatory, it can't be one spark and that's the end of the story. I do a lot of cell culture work, and the mycelium grows out like neurons. It takes time for those cellular divisions to occur. So titrating these medium doses takes time.
Also, clinical studies are very expensive. What's the motivation for a clinical study if you don't have protection of IP? Who's going to make the investment? It's very difficult to find phase two studies. Phase one studies cost $500,000 to $2 million a piece typically. They're safety studies. Phase two studies looking for an effect are in the $5 to $20 million range. There's a lack of funding. There's not the vehicle of profitability and investment in intellectual property to get these studies funded. So the lack of studies should not impugn the potential effects of these compounds. It's just a fact that the economic landscape does not support natural products research to phase two and phase three.
Artemisin came from Artemisia — active against malaria. That's a great example of a natural product that did make it through clinical trials. Lion's mane and cordyceps — it takes time for these effects to be seen. Oxygen intake and performance enhancement occur over time. It's not an immediate thing. Coffee can wake you up in one or two hours, but it's not going to actually be beneficial in the long term in the ways we're trying to talk about here.
Huberman: I'm grateful you pointed that out, because I think a lot of people have encountered products with cordyceps and will take it thinking there's going to be an acute cognitive enhancing effect. It makes perfect sense to me now why in many cases it wouldn't have that acute effect, but when taken continuously for some period of time might upregulate brain-derived neurotrophic factor. The blood flow argument you make about niacin makes tons of sense — everything we know about the cognitive enhancing effects of exercise are both acute, because of the increase in alertness which allows us to focus, as well as the improved blood flow and cerebrovascularization effects. The notion of blood flow delivery of chemicals and neuronal activity — it all jibes.
Mycelial electrical signaling and the neural network of nature
Huberman: These days you can find a lot of chatter on the health internet about things like grounding — putting feet on the ground, electrical grounding, magnetic fields. As somebody deeply embedded in the research on circadian biology and sunlight, to me it's not that wacky, but we need more data. I'm very interested in how fungi might have electrical signaling both between each other and with other organisms, meaning us. I'm fascinated by this idea that there are electrical fields being passed laterally but also to other organisms through these fungi.
Stamets: I postulated that mycelium would be micro-computers in one of my books in 2004, Mycelium Running: How Mushrooms Can Help Save the World. I was lambasted by the critics and skeptics. Now we know there are 50 word packets — discrete electrical word packets — that have been discovered signaling through mycelial networks. They are conductive. They hyperaccumulate heavy metals. We know these are electrical signals passing that alert the mycelium to food, to predators. We don't know exactly what all the words mean, but they're distinct word packets. We know 50 immediately. Do the algorithm — how many potential sentences can you create? So we know this signaling is going on.
I think we are in constant biomolecular communication with our ecosystems. The mycelium being an externalized neural network — I described it as not only a neural network of signaling, which we now know to be true, but also externalized lungs, because they're exhaling carbon dioxide and inhaling oxygen. They're externalized stomachs because they digest nutrients externally. This is a very efficient structure for accomplishing three things.
I have just been in communication with one of the owners of Clark Shoes. We started jamming on these ideas. The idea we started focusing on is: since every footprint you take, you're stepping on literally hundreds of miles of mycelium — if you could create a neural net interface with your shoes, and then with mycelium-like garments and hats, you then become these neurological membranes connected with nature, both for weather systems and for contact with celestial signaling. You could extend your neural sensitivity networks by using mycelial interfaces. The idea of being able to walk across the landscape and have neurological communication with the ecosystem around you — it's actually happening already. The mycelium, I strongly believe, is sensitive to every footstep that we take. It knows that you are there.
Why wouldn't it? You break a twig, there's competition of the mycelium to grab that twig to digest it. Competition is a good thing, especially with a diversity of fungi trying to grab more nutrients. It just seems to me de facto to be true that these neural networks and the mycelial networks are constantly in communication, constantly in competition. What if we start seeking alliances with these mycelial networks in nature? What will that do to expand our consciousness of nature and tapping into the deep intelligence of these mycelial networks? This is where AI could come into place. If it's raining, it would be more conductive. What would the membrane be — copper meshes? What would the interface be? This is just the beginning of this idea. Lots of young scientists could take this idea and run with it.
We know these mycelial networks are neural networks. Now it sounded crazy back when I described it. Now other scientists are saying yes. A lot of my ideas that were very fringe are now considered accepted science. That's the pace of science.
I want to share something with you. I'm an amateur astronomer — capital A amateur, small A astronomer. I really wanted to be an astronomer before I became a mycologist. I'm just blown away by the cosmos. There have been amazing discoveries made on asteroids in the past 10 years. First, a Japanese asteroid retrieval from a probe brought back the basic amino acids that build DNA — ACGT. But another asteroid retrieval is especially interesting — asteroid Bennu. In 2016, NASA sent a probe to Bennu. It took two years to get there, about a year and a half circling the asteroid to figure out where to land. They landed the probe, retrieved some asteroid dust, and it took about two years to come back. In November of 2025, NASA announced not only that they found amino acids — 14 essential amino acids found so far — but they found something else. They found tryptophan on Bennu. Tryptophan is very fragile, so other asteroid retrievals and meteorites couldn't find this amino acid. But they found tryptophan — precursor to serotonin.
The tryptamine universe hypothesis
Stamets: Tryptophan decarboxylates — liberates carbon dioxide in one very simple chemical reaction — into tryptamines. Think about it, Andrew. We have tryptamines throughout the universe. We have serotonin likely throughout the universe. These are tryptamine alkaloids. These are happiness molecules. The entire universe is likely filled with tryptamines. And if we have these networks of cells generating tryptamines, it dawned on me that we live in a tryptamine universe. We live in a universal field of consciousness. We'll find mycelium-like organisms throughout the entire universe because that is the way of our neurology. That's the way of mycelium. That's the way of the computer internet. That's the way of dark matter. We may live in this one giant universal consciousness. And we're tiny little apes looking up into the sky wondering what's going on.
This, I think, unifies all religions. It unifies scientists who are becoming increasingly more spiritual. To me, this is mind-boggling, and it makes me feel much better about my own mortality. I'll be sad when I die in a sense, but I'm returning to the giant universal consciousness from which we came and of which we are a part right now. This is what I believe intuitively as a fundamental truth.
Huberman: I'm becoming more and more convinced that our ideas about the brain and biology, while many of them are accurate, are certainly incomplete. The openness that you have, and these observations which are coming in faster and faster all the time, is exciting. But let's be serious scientists — where's the proof? Where's the logic in this? Let's stress-test this.
Stamets: And this is what I'm seeing over and over again — these extraordinary imaginative concepts. We can dare to be wrong. It's important that we dare. It's important that we think creatively, not constrained by tradition, but question. I had a sticker on my car for a long time: "Question Authority." And I put underneath it, "with respect and humor," because I thought that's the way you create a dialogue. You don't insult somebody. You question them and ask them why they think this way, and both of you can create a dialogue and your imaginations are stimulated. I just think we're at a time of great imagination, and this is a time to potentiate the imagination of humans. I think psilocybin and these mushrooms are force multipliers to expand our immunological and neurological health.
Electrical fields, the mycobiome, and fungi living on and in us
Huberman: I have a question about these electrical fields. You talked about a hypothetical arrangement where we had spikes that would go into the ground and you could transmit those electrical fields into the body. We are of chemicals and electricity — that's not a mystical statement, that's how neurons work. The notion of electricity in the brain hopefully doesn't make people think this is really out there. That's a fundamental concept. So that's us getting closer to and more direct interface with these electrical fields. What about the electrical fields and the chemicals from these fungi living in us? Most people nowadays have heard of the microbiome — the microorganisms that live in us that can be beneficial or in cases of dysbiosis can be harmful. You've talked about the mycobiome — we have fungi living inside of us.
Stamets: We have a lot of fungi living on our skin. Our skin is one of our biggest organs, and the microbiome of the skin gives us a homeostasis of protection against disease. It's when we use antifungal antibiotics in particular that it can really disrupt the microbiome. I have a horrible story of a friend's father who took an antifungal medicine, had an allergic reaction, got thrush, got candida, and he was a big strong man. Apparently his death was so painful — brutal — because it was brutal. That's an example of the danger of some of these pharmaceutical antifungals.
We're more closely related to fungi than any other kingdom. We share in common many of the same pathogens. So we use antifungal medicines, and this is why it's so hard to get rid of fungal infections — they also tend to be cytotoxic. The microbiome on the skin is something that's being greatly explored. The microbiome internally in the gut is much poorer in our understanding right now. I can't speak authoritatively on the internal microbiome. Eukaryotic fungi and the eukaryotic cells of humans look very, very similar. Typically fungi living in and between your cells is not good from my limited understanding. The microbiome on the surface and in your gut and homeostasis is really important. The disruption of that is extremely dangerous.
So this is airing on the side of caution — just don't screw around with antifungals, because the disruption to homeostasis can be extremely bad. I don't have an authoritative answer for you. There are other experts out there — please consult them. They're easily discoverable. The American Dermatological Association has a lot of interesting ideas on the microbiome of fungi living on and within the skin cells.
Mycoremediation — what fungi can and cannot clean up
Huberman: Two more questions for you. The first is about the potential benefits of fungi for cleaning up the planet and maybe even the food supply. The ability of fungi to digest and break down other things is pretty remarkable. Nowadays most people in our egocentric old-world primate expanded-forebrain cells are thinking, "Okay, there's no way to avoid microplastics. There's no way to avoid the particulate that's out in the air." But most people would like to reduce the toxic burden of these things. Is there a way that fungi can be put into the environment in beneficial ways to clean the air, to sequester and maybe break down some of these compounds?
Stamets: I have literally spent millions, if not tens of millions of dollars on this subject. And I don't want to be a buzzkill, but I can tell you what I've learned. It has been painful and expensive. We have very good reproducible demonstrable examples that we have published on — mushroom mycelium like oyster mushrooms breaking down hydrocarbons, diesel, gasoline, bunker sea oil that ships are burning from oil spills. Really good. The mycelium takes these polyaromatic hydrocarbons, PAHs, breaks them down at the elemental level, and reassembles them into fungal carbohydrate sugars. I worked with Battelle Laboratories for years. We broke down bunker sea oil from, I think, 20,000 parts per million to 200 parts per million in 16 weeks using oyster mushrooms. Approved for freeway landscaping. It passed the Department of Ecology tests. That works.
So oil spills, mulching — mushroom farms should be reinvented as mycoremediation supply centers, because the waste substrate after the mushrooms form, you can milk it like a cow. It is so full of powerful enzymes that can break down complex molecules. For that, it's really, really good.
Breaking down dioxins and PCBs — polychlorinated biphenyls — from my research has been a disaster. It's very alluring because even though we could break down the dioxins in a petri dish in a laboratory, when we put the mycelium out into the ecosystem, think of it this way: it's like you have a buffet table and you're the fungus and you're hungry. You have all this delicious food on the buffet table, and at the end of it is this toxin, dioxin. What are you going to eat first? You're going to eat the delicious food. If you starve the mycelium, it will break down the dioxin. So dioxin remediation is just not practical in the real world.
Similarly, breaking down plastics — there are some really good examples published for breaking down plastics. But similarly, you throw the mycelium in an ecosystem and it's going to navigate to the foods that are most desirable. Plastics are not something that is high on their list of desirability. I wish I had good news on dioxins, PCBs, and plastics. Some of these recalcitrant polymers that are very tightly bonded — what's the incentive for the mycelium to go after microplastics, which are a small percentage of the food buffet in front of it?
The untapped resource is mushroom farms and their waste substrate. You can compress it, get this beautiful amber liquid super high in complex enzymes, then reinflate it by adding water, and the mycelium can produce another flush. I proposed this in my book Mycelium Running — mushroom farms should be reinvented as mycoremediation centers in every small city.
The other area that's been very successful is microfiltration of E. coli and other contaminants associated with runoff. The mycelium is a filtration membrane. Very good examples have been published in several peer-reviewed journals of mycelial networks capturing E. coli, preventing effluence from farms — chicken farms, cattle ranches — from going into waterways. So the good news is hydrocarbons in general, pesticides, and even things like VX nerve gas agents where there are chemical spills — many of these things are very fragile compounds when the enzymes the mycelium makes contact with them. Microfiltration of bacteria and breaking down of these chemicals — that's really good.
The bad news is dioxins and some of these other compounds. Mycelium does have the ability of sequestering radioactive particles and binding them in a way that is not soluble into water. So it can immobilize some of these toxins — that's a whole different approach, immobilization to prevent it from getting into the food chain.
When people approach me on this stuff, I just have to bite my tongue because I spent so much money with great scientists. We have some fantastic successes. But the reality is where I'm going to spend my valuable time — I'm going to spend it on optimization, on longevity, on making people nicer and creating generations of happiness, because the pebbles of the pond of happiness and positivity that we create now will reverberate into the generations of the future.
Paul Stamets' longevity protocol — push-ups, mushrooms, and staying young at 71
Huberman: I certainly second that choice because it's benefiting so many. One last question. Let's talk push-ups. How many push-ups are you doing each day?
Stamets: I did 95 this morning.
Huberman: You're very vigorous — that's why I asked. Maybe share your longevity protocol.
Stamets: I need to lose some weight, but I haven't been on my bike in the past two weeks. It's a good story because my twin brother — his name is North. So of course I was called South. Very competitive, fraternal twins, as different as two twins can be. But we were extremely competitive, and that was a good thing about having a twin brother.
We started doing these marathon push-ups ever since I was like 10 years of age. Actually, I won the push-up contest in Columbiana, Ohio. I was a freshman, in the ninth grade. They opened it up for 9th, 10th, 11th, and 12th graders — lots of guys bigger than me. They had a push-up contest. My twin brother and I said, "Oh, we can do this." I started doing the push-ups and the coach stopped me after 20 seconds — I'd already done like 30 or 40 push-ups. He said, "No, your nose has to hit the auditorium basketball floor." So he laid down to see if my nose would hit. I started doing the push-ups and ended up getting a bloody nose, pushing up like 40, 50, 67, with blood splattering all over the place. And I did it. I won the contest, and the record held for a long time.
But I point everyone to a Harvard study. Please look this up. It's really extraordinary. Men who can do 40 push-ups — and I'm sure it translates to women, a different number of course — if you can do 40 push-ups three times a week, you have a 97% reduction in the potential for cardiac arrest.
Huberman: Are all those push-ups done in a single set?
Stamets: Single set. You have to look it up, but the study — I've looked it up many times and referred to it to many people. Fact-check me. This is true. Full disclosure, I don't hyperextend my push-ups. I don't go nose to the ground because I don't want to hyperextend my elbows past my body. I go to about this far off the ground.
Huberman: Break 90 degrees at the elbow.
Stamets: Yeah, just at my comfort. I can know when I hyperextend because my elbows hurt later on. I just advocate this. This is probably the most actionable thing that anyone can do — women included. Do push-ups. Do a stress test.
I just came from several conferences on biohacking and I'm learning a lot that I didn't know. These chair sit-ups, deep squats — those are something I'm going to start incorporating. But I'm 71 years of age. I have no prescription drugs. I feel like I'm 35. I was born July 17th, 1955. I just can't believe I'm 71 years of age because I look through these eyes and I don't feel it. I don't feel cognitive decline either. But I attribute that to my use of these mushrooms because they're neuro anti-inflammatories in my opinion and of one study. Plus the excitement of the field that you are in breeds creativity. It breeds conversations like this and upregulates my immunity. It's anti-inflammatory by definition. Happiness is the anti-inflammatory drug ultimately. That's what we're seeking.
Huberman: I certainly believe that curiosity driving constructive, productive inquiry and community — Paul, thank you so much for coming here today to discuss your discoveries and your work and the applications. You provide a lot of actionable steps for people to explore and consider, and also just a lot of — I was going to say seeds, should we say spores — for exploration in mental health, in immune system function, cognitive enhancement. I have to say your enthusiasm around the tryptamines in the universe concept is one that certainly sparks a lot of interest in me.
It's clear to me, if I may, that you are very unusual in your ability to think about very high-level, literally galaxy-and-beyond-wide concepts, but then come right down to the highly reductionist view and go back and forth — traveling back and forth — which is unusual. And it no doubt has fueled the forward progression of this area of science and medicine. You're very humble, and I know this might feel a little uncomfortable for you, but having studied a lot of the history of science and medicine and public health, and the way it's progressed, it's always required somebody like you to be able to not just straddle but really travel back and forth in the same conversation from these high-level, at times somewhat abstract concepts, but then get right back to the grounding of things and explain what we need to know in addition to what you are intuiting based on your knowledge and what we already know. You mentioned N of one — you are an N of one, and I and many many other people are extremely grateful, and I'm sure that will be true across time for the work that you're doing. Thank you for taking the time to come share your knowledge.
Stamets: Well, thank you for being a fellow edge runner. I just want to call out to everyone — be creative, because creativity breeds happiness and it breeds community. And then you have the cross-talk of all these receptors that are all in communication and dialogue. This is an opportunity for us to reinvent the human species, to optimize. I would just caution everyone, including myself — be careful about criticizing people until you understand why. Ask the question why. Never take anything that you hear as a fact without asking the question why, with humility, respect, kindness, and engagement. That's how you build these bridges. Our neuro-receptors want to talk to your neuro-receptors. We're all in this together.
I think we have an opportunity for a collective genius to come together to find the solutions that we so need. I really feel it's so important. First Nations people — the concept of seven generations is so true, so important. Indigenous peoples have the wisdom that scientists are now proving to be factually true with a different language, but the endpoints are the same. We have a duty to our descendants to do the best that we can. It's not what you make in your lifetime. It's the legacy that you leave. I think all of us can be part of a wonderful legacy if we work together.
Huberman: Amen to that. I don't have anything to add. Perfectly stated. Thank you.